- Molecular NameMefruside
- SynonymNA
- Weight382.889
- Drugbank_IDN/A
- ACS_NO7195-27-9
- Show 3D model
- LogP (experiment)1.54
- LogP (predicted, AB/LogP v2.0)1.61
- pkaN/A
- LogD (pH=7, predicted)1.6
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.98
- LogSw (predicted, AB/LogsW2.0)0.02
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors2
- No.of HBond Acceptors7
- No.of Rotatable Bonds5
- TPSA123.53
- StatusN/A
- AdministrationN/A
- PharmacologyA diuretic indicated for the treatment of edema and hypertension.
- Absorption_valueN/A
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)6 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma : whole blood ratio, about 0.03.
- MetabollsmN/A
- Half lifemefruside 3 to 12 h (mean 7), 5-oxomefruside 10 to 14 h, hydroxycarboxylic acid analogue 8 to 12 h.
- ExcretionAbout 13% of a dose is excreted in the urine as 5-oxomefruside, about 35 to 55% as the hydroxycarboxylic acid analogue of 5-oxomefruside and up to about 15% as a conjugate of this acid analogue. Both of these metabolites appear to be active. Less than 1% of the dose is excreted as unchanged drug.
- Urinary ExcretionN/A
- ClerancePlasma clearance, 5 to 30 mL/min/kg (mean 13).
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A